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Abstract
 
Toll-like receptor 4 (TLR4)-mediated recognition of lipopolysaccharide (LPS) is required for
efficient recognition of Gram-negative bacterial infections. Two commonly occurring muta-
tions in the human TLR4 gene (Asp299Gly and Thr399Ile) have recently been shown to be
associated with blunted physiological responses to inhaled LPS, and with increased risk of
Gram-negative bacteraemia in sepsis patients and reduced risk of atherosclerosis in an Italian
population. Here we show that monocytes from individuals heterozygous for both mutations
 
in the TLR4 gene exhibit no deficit in recognition of LPS of 
 
Escherichia coli
 
, 
 
Neisseria meningitidis
 
,
 
Bacteroides fragilis
 
, 
 
Yersinia pestis
 
, 
 
Chlamydia trachomatis
 
, 
 
Porphyromonas gingivalis
 
, or 
 
Pseudomonas
aeruginosa
 
. We propose that the relatively high frequency of these mutations in the Caucasian
population may reflect modified responses of carriers to alternative TLR4 agonists.
Key words: lipopolysaccharides • Toll-like receptor 4 • single nucleotide polymorphism • 
monocytes • innate immunity
 
Introduction
 
The innate immune responses of mammalian species have
evolved to provide the host with a rapid detection of and
reaction toward microbial products. Such responses are es-
sential to allow efficient combatting of infection. A family
of pattern recognition proteins termed the Toll-like recep-
tors (TLRs) has recently been discovered and shown to be
capable of recognizing a wide range of conserved patho-
gen–associated molecules. The human genome contains
genes coding for at least ten TLRs (1), most of which have
been shown to be capable of recognizing microbial products.
The majority of bacterial lipopolysaccharides, for exam-
ple, are recognized by TLR4, though there have been re-
 
ports that the LPS of 
 
Porphyromonas gingivalis
 
 and 
 
Leptospira
interrogans
 
 may be recognized by TLR2 (2, 3).
Two common mutations in the human TLR4 gene,
Asp299Gly and Thr399Ile, have been observed to occur at
a frequency of between 6 and 10% in Caucasian popula-
tions (4). Individuals heterozygous for these, typically co-
segregating, mutations have been shown to have reduced
airway responsiveness to inhaled 
 
Escherichia coli
 
 LPS (5).
Furthermore, primary airway epithelial cells of individuals
heterozygous for these mutations were shown to be incapa-
ble of producing IL-1
 
 
 
 in response to LPS challenge,
whereas this response was intact in cells extracted from
wild-type individuals (5).
As these mutations have been shown to exist at a rela-
tively high frequency in the Caucasian population (4), we
set out to determine whether expression of the mutant allele
conferred on carriers any advantage in terms of their ability
to respond to the LPS of organisms other than 
 
E. coli
 
. The
component of LPS recognized by TLR4 has been deter-
mined to be the lipid A moiety (6). For this reason, we
assembled a panel of seven different LPS types representing
diverse lipid A structures (for a review, see reference 7) to
determine if presence of the mutation altered responses to
the LPS of other bacterial species.
 
Materials and Methods
 
Detection of TLR4 Polymorphisms.
 
80 Scottish residents were
screened for the presence of the Asp299Gly and Thr399Ile alleles
according to the method of Lorenz et al. (4). Briefly, DNA was
prepared from whole blood using the ReadyAmp genomic DNA
purification system (Promega) according to manufacturer’s in-
structions. Genomic DNA (5 
 
 
 
l) was added to 25 
 
 
 
l of
ReadyTaq PCR mix (Sigma-Aldrich) supplemented with 0.2 
 
 
 
l
(20 pmol) of each primer and 19.6 
 
 
 
l of nuclease free water.
Primers for the Asp299Gly allele were (forward: 5
 
 
 
-GATTAG-
CATACTTAGACTACTACCTCCATG-3
 
 
 
, reverse: 5
 
 
 
-GAT-
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CAACTTCTGAAAAAGCATTCCCAC-3
 
 
 
). Primers for
the  Thr399Ile allele were (forward: 5
 
 
 
-GGTTGCTGTTCT-
CAAAGTGATTTTGGGAGAA-3
 
 
 
, reverse: 5
 
 
 
-ACCTGAA-
GACTGGAGAGTGAGTTAAATGCT-3
 
 
 
). Thermal cycling
was: 95
 
 
 
C for 4 min, then 30 cycles of 95
 
 
 
C for 30 s, 55
 
 
 
C for
30 s, and 72
 
 
 
C for 30 s. Asp299Gly or Thr399Ile PCR products
(20 
 
 
 
l) were digested with NcoI (Promega) or HinfI (Promega),
respectively, and visualized on a 3% high resolution agar gel
(Nusieve 3.1; Flowgen). Genotypes of the six individuals re-
cruited for further testing were confirmed by sequencing. Ap-
proval for the study was granted by the Lothian Research Ethical
Committee (LREC no. 2000/5/35).
 
Preparation of LPS.
 
LPS of 
 
Escherichia coli
 
 R1 (NCTC 13114),
 
Neisseria meningitidis
 
 (MPRL-2843), 
 
Bacteroides fragilis
 
 (NCTC
9343), 
 
Pseudomonas aeruginosa
 
 (PAC 611), and 
 
P. gingivalis
 
(MPRL-1675) were reconstituted from frozen laboratory stocks
previously prepared using either the phenol/chloroform/petro-
leum (
 
E. coli
 
, 
 
B. fragilis
 
, 
 
P. aeruginosa
 
), triton/MgCl
 
2
 
 (
 
N. meningi-
tidis
 
), or phenol/water method (
 
P. gingivalis
 
) as described previ-
ously (8). LPS of 
 
Chlamydia trachomatis
 
 (LGV-1) and 
 
Y. pestis
 
were gifts of Dr. A. Eley (University of Sheffield, Sheffield, UK)
and Dr. P. Oyston (DSTL, Porton Down, UK), respectively. All
LPS samples (except that of 
 
C. trachomatis
 
, of which only 8 
 
 
 
g
was available) were repurified to remove protein and lipoprotein
contamination according to the method of Hirschfeld et al. (9).
Lipoteichoic acid of 
 
S. aureus
 
 was purchased from Sigma-Aldrich.
 
Separation of Monocytes.
 
Whole venous blood was collected
from three individuals homozygous for the wild type TLR4 al-
leles, and three individuals heterozygous for the Asp299Gly and
Thr399Ile polymorphisms. All volunteers were healthy at time
of testing and were not undergoing any drug therapy other than
oral contraceptives. Blood diluted 1:3 in PBS (40 ml) was lay-
ered onto 10 ml of Histopaque-1077 (Sigma-Aldrich) and cen-
trifuged at 300 
 
g
 
 for 30 min. Peripheral blood mononuclear cells
were removed from the interface and washed twice (7 min,
300 
 
g
 
) in PBS before being counted and resuspended in RPMI
supplemented with antibiotics and 10% human AB serum
(Sigma-Aldrich) at 10
 
6
 
 monocytes per ml. Cells were then plated
at 100 
 
 
 
l per well of a 96 well plate (Iwaki) and incubated for
1 h at 37
 
 
 
C/5%CO
 
2
 
. Non-adherent cells were removed with
four rinses with PBS.
 
Challenge of Monocytes.
 
Serial 10-fold dilutions of each LPS
were made in RPMI supplemented with 10% human AB serum
(Sigma-Aldrich) and 100 
 
 
 
l of each dilution was added to cells.
Control cultures were incubated in medium alone. After 4 h in-
cubation, supernatants were assayed for IL-1
 
 
 
 production using
the Duoset ELISA system (R&D Systems) according to the man-
ufacturer’s instructions.
 
Results and Discussion
 
A screen of 80 Scottish residents revealed 8 individuals
heterozygous for the Asp299Gly and Thr399Ile polymor-
phisms in the TLR4 gene. Each individual carried both
mutations, confirming the earlier observation that these
mutations are rarely seen to segregate individually (10). Fig.
1 shows the results of genotyping of three individuals het-
erozygous for the TLR4 mutations and three individuals
expressing wild-type TLR4. Monocytes from these six,
roughly sex and age matched, individuals were challenged
with LPS of 
 
E. coli
 
, 
 
N. meningitidis
 
, 
 
B. fragilis
 
, 
 
Y. pestis
 
, 
 
C.
trachomatis
 
, 
 
P. gingivalis
 
, 
 
P. aeruginosa
 
, and lipoteichoic acid
of 
 
S. aureus
 
. Fig. 2 shows that no appreciable difference ex-
ists in the responses of wild-types and heterozygotes to any
of the LPS tested. Statistical analysis reveals that no signifi-
cant difference exists in the response of wild type or het-
erozygote monocytes to any of the panel of LPS investi-
gated at any of the concentrations tested (Table I). It is also
clear when viewing the data in this way that the capacity of
the different LPSs to stimulate cells varies substantially. For
example, responses to the LPS of 
 
E. coli
 
 and 
 
N. meningitidis
 
are strongest, while responses to 
 
B. fragilis
 
, 
 
P. gingivalis
 
, and
 
Y. pestis
 
 LPS are somewhat reduced and LPS of 
 
C. tracho-
matis
 
 and 
 
P. aeruginosa
 
 show the lowest activity.
It was expected that the responses of wild-type and het-
erozygote monocytes to 
 
S
 
. 
 
aureus
 
 LTA should be broadly
similar as the signaling of this molecule is thought to be
TLR4 independent (11). This differential signaling could
also explain the identical responses made toward 
 
P. gingiva-
lis
 
 LPS as this molecule has been shown to be capable of
signaling via TLR2 (2), though it should be pointed out
that the LPS of at least one strain of 
 
P. gingivalis
 
 has been
shown to signal via TLR4 (12). However, the responses of
heterozygotes to every other LPS tested are at odds with
recent reports of the reduced functional capacity of cells
isolated from such donors. Arbour and coworkers have re-
ported that individuals heterozygous for these mutations
have blunted physiological responses to inhaled endotoxin
and while airway epithelia from wild-type individuals are
capable of secreting IL-1
 
 
 
 in response to LPS in vitro,
cells from heterozygotes were shown to be incapable of
this response (5).
There are several possible explanations for the discrep-
ancy between the findings of these workers and the cur-
rent study. First, airway responses to LPS are known to be
highly variable between healthy donors (13). Arbour and
colleagues categorized study subjects challenged with in-
haled endotoxin as ‘LPS responsive’ if their forced expira-
Figure 1. Detection of wild-type, Asp299Gly, and Thr399Ile alleles in
the human TLR4 gene. Genomic DNA of individuals recruited into the
current study was amplified according to the method of Lorenz et al.
(reference 4). PCR products were digested with the enzymes NcoI (299
allele) or HinfI (399 allele). Lanes 1 and 14, 100 base pair marker. Lanes
2–7, RFLP of the 299 section of TLR4 gene from three wild-type donors
and three heterozygotes. Lanes 8–13, RFLP of the 399 section of TLR4
gene from three wild-type donors and three heterozygotes. Top band
represents presence of wild-type allele, bottom band indicates presence of
mutant allele. Genotypes were confirmed by sequencing.T
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tory volume in one second (FEV
 
1
 
) was reduced by at least
20% at any stage following endotoxin challenge. Using
this cut off, they state that the mutation was present in 3 of
52 normal responders and 7 of 24 hyporesponders. Using
Fisher’s one-tailed exact test of these ratios, the group cite a
P value of 0.029, though the more appropriate chi-
squared analysis of these ratios would have indicated no
significant difference in allele frequency between these
two groups (P 
 
  
 
0.0539). Most significantly, however, the
authors point out that not everyone in their study with the
TLR4 mutation was hyporesponsive to LPS and that some
of the individuals hyporesponsive to inhaled LPS in their
study expressed wild-type TLR4. With this in mind, we
feel it is more likely that the differences in airway respon-
siveness to LPS observed by Arbour and colleagues are de-
termined not by the presence of these mutations, but in-
stead by such factors as the circulating levels of LBP and
soluble CD14, the number of LPS responsive cells present
in the airway at time of testing and the current expression
level of TLR4 – itself understood to rise and fall in re-
sponse to various stimuli.
To remove bias from modulating factors such as these,
we investigated the LPS responsiveness of monocytes de-
rived from different donors in vitro. Using this approach
allowed much of the interindividual variability to be re-
moved, as factors such as cell number and differences in
serum constituents could be controlled for. Arbour and
colleagues investigated the in vitro responses of airway epi-
Figure 2. IL-1  secretion of
wild type and Asp299Gly/
Thr399Ile heterozygote TLR4
monocytes in response to LPS
and LTA challenge. Human
monocytes were challenged
with ten-fold serial dilutions of
E. coli, N. meningitidis, Y. pestis,
C. trachomatis,  B. fragilis,  P.
aeruginosa, P. gingivalis LPS or S.
aureus LTA, or medium alone
(C). Supernatants were assayed
for IL-1  content after 4 h incu-
bation. Open circles represent
mean IL-1  secretion    SEM
from three wild-type donors.
Filled squares represent mean
IL-1  secretion    SEM from
three donors heterozygous for
both TLR4 mutations.T
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thelial cells and showed that while epithelia from wild-type
individuals were capable of secreting IL-1
 
 
 
 in response
to LPS, cells from heterozygotes appeared to be incapable
of this response (5). This finding is clearly in contrast with
the observations of the current study, a difference which
may perhaps be explained in two ways. First, it is possible
that the mechanisms for regulation of TLR4 are different
in monocytes and airway tissues, such that presence of the
mutation in the latter may lead to down-regulation of
TLR4 expression. Second, it is worth noting that the LPS
used in Arbours study was a commercially bought sample
of 
 
E. coli
 
 serotype O111:B4 LPS. Some commercial prepa-
rations of LPS have been shown to contain substantial
amounts of protein and lipoprotein contamination (2), a
property of most LPS preparations prepared using tradi-
tionally employed methods (14). It has been shown that re-
moval of these contaminants can be achieved using a phe-
nol reextraction technique (9). For this reason, each of the
LPS used in the present study was repurified according to
the protocol described by Hirschfeld et al. (9) (except that
of 
 
C. trachomatis
 
 of which not enough material was avail-
able to facillitate efficient purification). Thus, it remains
possible that the blunted responses documented by Arbour
et al. occurred as a result of impaired recognition of either
heat shock protein or another TLR4 agonist present in
their preparations. Certainly, the concentration of LPS
used in their study (100 ng/ml) was 
 
 
 
10,000 times more
than that required to detect pure LPS signaling, allowing
the possibility that alternative TLR4 agonists may exist at a
high enough concentration in their experiments to evoke
additional TLR4 signaling. Further experiments using pu-
rified LPS will be required to resolve this issue.
Researchers from the same group have also contributed
to several studies suggesting that the presence of these mu-
tations correlates with outcome in a number of clinical
conditions. As each of these studies has relied heavily on
the citation of Arbours observation that the allele confers
LPS hyporesponsiveness, it is worth considering the find-
ings of these studies in the light of the current study.
The Asp299Gly mutation, for example, has been seen to
occur at a higher frequency in septic shock patients than in
healthy controls (15) and a study of premature birth in
Finnish infants revealed a statistically significant correlation
between presence of the mutation in the infant and prema-
ture birth among singletons (P 
 
  
 
0.024; reference 16). An
association study investigating risk of atherogenesis in an
Italian cohort consisting of 810 individuals revealed 55 in-
dividuals harboring the Asp299Gly mutation (10). These
individuals demonstrated lower plasma levels of certain
proinflammatory cytokines, acute-phase reactants, and fi-
brinogen. Also, these individuals were found to be more
susceptible to severe bacterial infections, but demonstrated
a significantly lower risk of carotid atherosclerosis and a
smaller intima-media thickness in the common carotid ar-
tery (10). In contrast to the findings of these studies, how-
ever, a study of 237 patients receiving hematopoietic stem
cell transplantation revealed that the frequency of onset of
Gram-negative bacteraemia in patients with TLR4 muta-
tions was not significantly different from wild-type individ-
uals (17) and an unrelated group has reported no associa-
tion between presence of the Asp299Gly mutation and
either susceptibility to or severity of meningococcal disease
in a study of over 1,000 patients (18).
It is worth noting that where significant correlations
were shown in these studies, no correction for multiple
analysis was offered. Furthermore, the study of septic pa-
tients found 5 of 91 patients and 0 of 73 controls to harbor
the Asp299Gly allele in the absence of the normally coseg-
regating Thr399Ile allele (15). The authors cite a P value of
0.05 for this comparison using Fisher’s one-sided exact test,
though the more appropriate chi-squared analysis of these
ratios would have indicated a P value of 0.115.
It remains possible, however, that expression of variant
TLR4 is capable of altering the host response to TLR4
ligands other than LPS. Indeed, several other microbial and
host-derived products have also been shown to signal via
this molecule. For example, F-protein of respiratory synci-
tial virus (19), extra domain A of fibronectin (20), and both
human (21) and bacterial heat shock protein (22) have all
been shown capable of activating cells via TLR4. There-
fore, while the responses to LPS may be identical between
wild-types and heterozygotes, this does not preclude the
possibility that these mutations may alter the ability of indi-
viduals to detect other microbial products. Larger associa-
tion studies may yet therefore discover a correlation be-
tween presence of the mutation and disease progression. It
is possible, for example, that efficient recognition of Gram-
negative heat shock proteins may be significant in combat-
 
Table I.
 
Comparison of Homozygous Wild-Type and
Wild-Type/Asp299Gly,Thr399Ile Heterozygote TLR4-bearing 
Monocyte Recognition of Various LPS
 
Stimulus
Minimum
concentration
activating wild-type
monocytes
(ng/ml)
 
a
 
Minimum
concentration
activating
TLR4
 
 
 
/
 
 
 
 
 
monocytes
(ng/ml)
 
a
 
E. coli
 
 LPS 0.01 0.01
 
N. meningitidis LPS 0.1 0.1
B. fragilis LPS 1 1
P. gingivalis LPS 10 10
Y. pestis LPS 10 10
C. trachomatis LPS 100 100
P. aeruginosa LPS 100 100
S. aureus LTA 100 100
Homozygous wild-type or Asp299Gly/Thr399Ile heterozygous (TLR4 / )
human monocytes were challenged with 10-fold serial dilutions of
E. coli, N. meningitidis, Y. pestis, C. trachomatis, B. fragilis, P. aeruginosa,
P. gingivalis LPS, or S. aureus LTA or medium alone.
aMinimum concentration represents the lowest concentration at which
individual stimuli induce production of significantly more IL-1  (P  
0.05) than cells incubated with medium alone.T
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ting infection and it has already been shown that recogni-
tion of human heat shock proteins has a role to play in
atherogenesis (23).
In summary, our initial hypothesis that the described
mutations in the TLR4 gene may alter host responses to
the LPS of bacteria other than E. coli has proven to be un-
founded. Instead, we have shown that presence of these
mutations (at least in heterozygote carriers) has no effect on
the capacity of human monocytes to detect LPS of seven
different strains of Gram-negative bacteria. The marked
differences in in vivo LPS responsiveness between individ-
uals is therefore determined far more significantly by other
genetic and acquired traits of individuals, than by the pres-
ence of the Asp299Gly and Thr399Ile TLR4 mutations.
Further experiments will be required to determine whether
expression of these variant receptors results in modified ca-
pacity to respond to alternative TLR4 agonists.
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